Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Feb;4(1):53-8.
doi: 10.1016/S1525-1578(10)60680-0.

Spinal muscular atrophy genetic testing experience at an academic medical center

Shuji Ogino  1 , Debra G B Leonard, Hanna Rennert, Robert B Wilson
Affiliations

Spinal muscular atrophy genetic testing experience at an academic medical center

Shuji Ogino et al. J Mol Diagn. 2002 Feb.

Abstract

Approximately 94% of spinal muscular atrophy (SMA) patients lack both copies of SMN1 exon 7. We report our SMA genetic testing experience (total 1281 cases), using SMA linkage analysis (32 families), SMA diagnostic testing by PCR-RFLP (restriction fragment length polymorphism) to detect the homozygous absence of SMN1 exon 7 (and exon 8) (533 cases), and an assay to determine copy number of SMN1 exon 7 (SMN1 gene dosage analysis) (716 cases). SMN1 gene dosage analysis is used for SMA carrier testing as well as for the confirmation of a heterozygous SMN1 deletion in symptomatic individuals who do not lack both copies of SMN1. We conclude that comprehensive SMA testing, including SMN1 deletion analysis, SMN1 gene dosage analysis, and linkage analysis, offers the most complete evaluation of SMA patients and their families.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
An example of an ABI 373a electropherogram showing a one-base-larger SMN1 peak (actual size 188 bp, shown as 189 bp, arrow) in addition to the expected SMN1 peak (actual size 187 bp, shown as 188 bp, arrowhead), each corresponding to one SMN1 copy by gene dosage analysis. Each peak corresponds to PCR products of an SMN internal standard (SMNis), SMN2 genomic sequence (SMN2), SMN1 genomic sequence (SMN1, with a doublet), a CFTR internal standard (CFTRis), and CFTR genomic sequence (CFTR), from left to right, respectively. Numbers under each peak represent approximate product size in bp (top) and fluorescence intensity measured as an area under curve (bottom).
Figure 2.
Figure 2.
A flow chart of the results of SMA diagnostic tests and SMN1 gene dosage analyses for symptomatic and prenatal cases.
See this image and copyright information in PMC

References

    1. Munsat TL, Davies KE: International SMA consortium meeting (June 26–28, 1992, Bonn, Germany). Neuromuscul Disord 1992, 2:423-428 - PubMed
    1. Zerres K, Wirth B, Rudnik-Schoeneborn S: Spinal muscular atrophy: clinical and genetic correlation. Neuromuscul Disord 1997, 7:202-207 - PubMed
    1. Clermont O, Burlet P, Burglen L, Lefebvre S, Pascal F, McPherson J, Wasmuth JJ, Cohen D, Le Paslier D, Weissenbach J, Lathrop M, Munnich A, Melki J: Use of genetic and physical mapping to locate the spinal muscular atrophy locus between two new highly polymorphic DNA markers. Am J Hum Genet 1994, 54:687-694 - PMC - PubMed
    1. Soares VM, Brzustowicz LM, Kleyn PW, Knowles JA, Palmer DA, Asokan S, Penchaszadeh GK, Munsat TL, Gilliam TC: Refinement of the spinal muscular atrophy locus to the interval between D5S435 and MAP1B. Genomics 1993, 15:365-371 - PubMed
    1. Melki J, Lefebvre S, Burglen L, Burlet P, Clermont O, Millasseau P, Reboullet S, Benichou B, Zeviani M, Le Paslier D, Cohen D, Weissenbach J, Munnich A: De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science 1994, 264:1474-1477 - PubMed

MeSH terms